A review of animal models for autism spectrum disorder finds that oxytocin system disruptions occur in some ASD subtypes, suggesting oxytocin treatment may benefit specific subgroups rather than all individuals with ASD.
No approved drugs for core ASD social deficitsDespite oxytocin's promise as a social behavior peptide, its therapeutic use in autism requires better patient stratification — animal models suggest only certain ASD subtypes involve oxytocin system disruption.
What the researchers found
The review examined both genetic and environmental animal models of ASD in which the oxytocin system was investigated. Key findings include evidence that the oxytocin system is perturbed in specific animal models of ASD, and that oxytocin administration can improve ASD-associated social behavior deficits in some of these models.
Critically, the authors highlight that not all ASD subtypes involve oxytocin system disruption, and that the enormous heterogeneity of ASD may explain why clinical trials of oxytocin in humans have produced mixed results. They argue that perturbations in the oxytocin system should be investigated as potential stratifying biomarkers to identify which individuals are most likely to benefit from oxytocin treatment.
Why it matters
There are currently no approved drugs that treat the core social communication deficits of autism. Oxytocin has shown promise in some clinical trials but disappointing results in others. This review argues that the key to unlocking oxytocin's therapeutic potential may be identifying which specific subtypes of ASD involve a disrupted oxytocin system — a precision medicine approach that could transform how oxytocin is tested and used clinically.
How the study worked
This is a literature review examining published research on genetic- and environmental-based animal models for ASD. The authors surveyed studies that either investigated disruptions in the oxytocin system within these models or tested the effects of oxytocin administration on ASD-related behavioral phenotypes.
What this study cannot tell us
As a review of animal studies, the findings have inherent limitations in translating to human ASD, which is far more heterogeneous and complex than any single animal model can capture. The review does not present new experimental data. The availability of validated biomarkers for oxytocin system perturbation in humans remains limited, making the proposed stratification approach challenging to implement clinically.
How to read the evidence
This is a narrative review of preclinical animal research. While it synthesizes an important body of evidence, reviews of animal studies sit below clinical trial evidence and systematic reviews in the evidence hierarchy. The conclusions about human treatment are inferential.
When this study was published
Published in 2018, this review captures a period of active clinical and preclinical interest in oxytocin for autism. Since then, several human clinical trials have reported mixed results, consistent with the authors' call for better patient stratification.
The bigger picture
This review reflects a broader shift toward precision medicine in autism research. Rather than testing oxytocin as a blanket treatment for all ASD, the field is moving toward identifying biomarkers that predict who will respond. Animal models provide a controlled way to dissect these subtype-specific mechanisms that are impossible to study directly in the heterogeneous human ASD population.
Questions still open
- Can biomarkers of oxytocin system disruption be reliably measured in humans to identify which individuals with ASD would benefit from oxytocin treatment?
- Would long-term oxytocin treatment produce lasting social improvements, or are effects only present while the peptide is being administered?
- Could combination therapies that pair oxytocin with behavioral interventions be more effective than either approach alone?
Common questions
Why might oxytocin help some people with autism but not others?
What is oxytocin and how does it affect social behavior?
Read the original research
Oxytocin and Animal Models for Autism Spectrum Disorder.
Current topics in behavioral neurosciences, 35, 213-237
Citation
Wagner, Shlomo; Harony-Nicolas, Hala. (2018). Oxytocin and Animal Models for Autism Spectrum Disorder.. Current topics in behavioral neurosciences, 35, 213-237. https://doi.org/10.1007/7854_2017_15